{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T13:57:04Z","timestamp":1772287024491,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.msard.2019.101907","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T02:43:31Z","timestamp":1577328211000},"page":"101907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody"],"prefix":"10.1016","volume":"39","author":[{"given":"Miki","family":"Kojima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-1933","authenticated-orcid":false,"given":"Satoru","family":"Oji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Izaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baku","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikoaki","family":"Fukaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.101907_bib0001","article-title":"Blockade of IL-6 signaling in neuromyelitis optica","author":"Araki","year":"2018","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.msard.2019.101907_bib0002","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101907_bib0003","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2019.101907_bib0004","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorders","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2019.101907_bib0005","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody prodauction from plasmablast in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.msard.2019.101907_bib0006","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101907_bib0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00281-018-0723-8","article-title":"Sex differences in autoimmune disorders of the central nervous system","volume":"41","author":"Gold","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.msard.2019.101907_bib0008","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0009","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":".Treatment of neuromyelitis optica with rituximab","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0010","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0011","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0012","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","article-title":"Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica","volume":"260","author":"Kageyama","year":"2013","journal-title":"J. Neuro."},{"key":"10.1016\/j.msard.2019.101907_bib0013","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.msard.2019.101907_bib0014","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorders","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101907_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safty of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0016","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neuro."},{"key":"10.1016\/j.msard.2019.101907_bib0017","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalized myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2019.101907_bib0018","first-page":"204","article-title":"Efficacy of low-dose tacrolimus in patients with rheumatoid arthritis who had an inadequate response to disease-modifying antirheumatic drugs","volume":"28","author":"Kurose","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2019.101907_bib0019","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple scleroisis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2019.101907_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2019.101907_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000498","article-title":"2018. Rituximab-indused hypogammanglobulinemia in patients with neuromyelitis optica spectrum disorders","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.101907_bib0022","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-012-2044-y","article-title":"Effect of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a reviw of the literature","volume":"31","author":"Matsubara","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2019.101907_bib0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5217\/ir.2015.13.3.219","article-title":"Tacrolimus for the treatment of ulcerative colitis","volume":"13","author":"Matsuoka","year":"2015","journal-title":"Intest. Res."},{"key":"10.1016\/j.msard.2019.101907_bib0024","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101907_bib0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Mod. Rheumatrol."},{"key":"10.1016\/j.msard.2019.101907_bib0026","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1523-1755.2005.00461.x","article-title":"Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study","volume":"68","author":"Mok","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.msard.2019.101907_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.101907_bib0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cen3.12189","article-title":"Methotrexate is effective for the treatment of neuromyelitis optica spectrum disorders in Asian patient","volume":"6","author":"Ng","year":"2015","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.msard.2019.101907_bib0029","first-page":"2023","article-title":"Prevention of relapse of neuromyelitis optica","volume":"72","author":"Nomura","year":"2014","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.msard.2019.101907_bib0030","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-Positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0031","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ecco-jcc\/jjv175","article-title":"Long-term outcomes in stroid-refractory ulcerative colitis treated with tacrolimus alone or in combination with purine analogues","volume":"10","author":"Schmidt","year":"2016","journal-title":"J. Crohn's and Colitis"},{"key":"10.1016\/j.msard.2019.101907_bib0032","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of resuponse","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2019.101907_bib0033","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00296-008-0833-z","article-title":"Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis","volume":"29","author":"Suzuki","year":"2009","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.msard.2019.101907_bib0034","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/1352458514546793","article-title":"Corticosteroid and tacrolimus treatment in neuromylitis optica related disorders","volume":"21","author":"Tanaka","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101907_bib0035","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/jnnp.2008.145391","article-title":"Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations","volume":"79","author":"Takahashi","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2019.101907_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0037","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profilies in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101907_bib0038","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gavis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0039","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101907_bib0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.101907_bib0041","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:20Z","timestamp":1761900620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819309782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"alternative-id":["S2211034819309782"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101907","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101907"}}